Amgen Inc. (AMGN) Competitors & Peers
The 5 largest companies in the same industry as Amgen Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Competitor | $1,354.00 | P/E 44.0RSI 61Cap 1.28 T |
| JNJ | Peer | $276.22 | P/E 41.9RSI 59Cap 664.9 B |
| ABBV | Competitor | $291.31 | P/E 50.0RSI 60Cap 514.7 B |
| MRK | Peer | $146.73 | P/E 148.2RSI 51Cap 362.4 B |
| AZN | Peer | $186.43 | P/E 26.4RSI 69Cap 289.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- INOSupplier
Own 10-K customer-concentration disclosure: MedImmune = 78% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
McKesson is one of Amgen's primary pharmaceutical wholesale distributors, individually accounting for over 10% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CAHSupplier
Amgen distributes biologics through Cardinal Health as one of three major wholesalers, each exceeding 10% of Amgen's gross revenues.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CORSupplier
Amgen distributes biologics through Cencora as one of three major wholesalers, each exceeding 10% of Amgen's gross revenues.
Confirmed — SEC filing / public disclosuresec.gov ↗ - XNCRSupplier
Own 10-Q customer-concentration disclosure: Amgen = 44% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - PODDSupplier
Own 10-K customer-concentration disclosure: AmgenInc. = 15% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- REGNCompetitor
Amgen is a direct competitor, notably clashing over PCSK9 inhibitor patents (Repatha vs Praluent).
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
Amgen competes directly with AbbVie in the immunology segment (Amgen Enbrel/Amgevita biosimilar vs AbbVie Humira).
Model-inferred, unverified — treat as a lead, not evidence - REPLCompetitor
Competes in oncolytic immunotherapy; Amgen manufactures Imlygic (talimogene laherparepvec).
Model-inferred, unverified — treat as a lead, not evidence - NAMSCompetitor
New Amsterdam's oral obicetrapib targets cardiovascular markets served by Amgen's Repatha injections.
Model-inferred, unverified — treat as a lead, not evidence - TMOSupplier
Thermo Fisher supplies bioprocessing equipment, single-use bioreactors, and analytical instruments critical to Amgen's biologics manufacturing.
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
Amgen is developing MariTide, a highly anticipated GIP/GLP-1 bispecific molecule aimed directly at the obesity market dominated by Lilly.
Model-inferred, unverified — treat as a lead, not evidence - NVOCompetitor
Amgen's clinical pipeline for metabolic disorders positions it as a key future competitor to Novo Nordisk's Wegovy.
Model-inferred, unverified — treat as a lead, not evidence